IVVD
InvivydยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IVVD Profile
Invivyd, Inc.
A biopharmaceutical company that develops antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and pre-emergent coronaviruses
1601 Trapelo Road, Suite 178, Waltham, MA 02451
--
Invivyd, Inc., was incorporated in Delaware on June 3, 2020. The company is a commercial-stage company with a mission to rapidly and permanently deliver antibody-based therapies to protect vulnerable populations from the devastating consequences of the pandemic virus threat, starting with SARS-CoV-2. The company's proprietary INVYMAB platform approach combines state-of-the-art virus surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid and continuous generation of new monoclonal antibodies (" MABs ") to keep pace with the evolving viral threat.
